EU Approves Sanofi and Regeneron's Dupixent for Severe Asthma

Date : 07/05/2019 @ 15h39
Source : Dow Jones News
Valeur : Sanofi (SAN)
Cours : 82.68  0.23 (0.28%) @ 17h39
Sanofi Cours Graphique

EU Approves Sanofi and Regeneron's Dupixent for Severe Asthma

Sanofi (EU:SAN)
Graphique Historique de l'Action

6 Mois : De Avr 2019 à Oct 2019

Plus de graphiques de la Bourse Sanofi
   By Cristina Roca 
 

Sanofi SA (SAN.FR) and Regeneron Pharmaceuticals Inc. (REGN) said Tuesday that Dupixent has been approved for the treatment of severe asthma in the European Union.

The two pharmaceutical companies developed the drug jointly, they said in a press release.

Dupixent is approved in the EU to treat moderate-to-severe atopic dermatitis in adults, and has now been given approval by the European Commission to treat severe asthma with type 2 inflammation in adults and patients 12 years and older.

 

Write to Cristina Roca at cristina.roca@dowjones.com; @_cristinaroca

 

(END) Dow Jones Newswires

May 07, 2019 09:24 ET (13:24 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.
Dernières Valeurs Consultées
EU
GLE
Société Gé..
EU
ALU
ALCATEL-LU..
EU
PX1
CAC 40
ORA
Orange
FX
EURUSD
Euro vs Do..
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.


Inscrivez-vous maintenant pour créer votre liste d'actions personnalisée, en streaming.

Les cours EURONEXT (CAC 40, etc. ) et FOREX (les devises) sont en direct si connecté.
NYSE, AMEX, et ASX sont en différé d'environ 20 minutes. Les autres cours sont en différé d'environ 15 minutes.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Conditions Générales

P: V:fr D:20191017 01:11:18